JP7837873B2 - ヒト化抗TrkA抗体及びその使用 - Google Patents
ヒト化抗TrkA抗体及びその使用Info
- Publication number
- JP7837873B2 JP7837873B2 JP2022555685A JP2022555685A JP7837873B2 JP 7837873 B2 JP7837873 B2 JP 7837873B2 JP 2022555685 A JP2022555685 A JP 2022555685A JP 2022555685 A JP2022555685 A JP 2022555685A JP 7837873 B2 JP7837873 B2 JP 7837873B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- trka
- antibody
- igg4
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011307482.7 | 2020-11-20 | ||
| CN202011307482 | 2020-11-20 | ||
| PCT/CN2021/131343 WO2022105814A1 (en) | 2020-11-20 | 2021-11-18 | Humanized anti-trka antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549300A JP2023549300A (ja) | 2023-11-24 |
| JP2023549300A5 JP2023549300A5 (cg-RX-API-DMAC7.html) | 2024-10-28 |
| JP7837873B2 true JP7837873B2 (ja) | 2026-03-31 |
Family
ID=81595256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555685A Active JP7837873B2 (ja) | 2020-11-20 | 2021-11-18 | ヒト化抗TrkA抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230357411A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4247852A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7837873B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114516917B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021382828A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI880048B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022105814A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120360963B (zh) * | 2025-04-23 | 2026-02-27 | 广州芬瑞生物科技有限公司 | 干细胞外泌体制备方法及该方法制备的外泌体在治疗男性勃起功能障碍中的用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003501103A (ja) | 1999-06-10 | 2003-01-14 | アブジェニックス インク. | 非同種スイッチ領域を介して、ヒト抗体の特定のアイソタイプを産生するためのトランスジェニック動物 |
| JP2015520182A (ja) | 2012-06-08 | 2015-07-16 | グレンマーク ファーマシューティカルズ, エセ.アー. | アミノ酸置換を有するヒト化抗TrkA抗体 |
| US20160244529A1 (en) | 2012-06-13 | 2016-08-25 | Rottapharm Biotech S.R.L. | Anti-trka antibodies, derivatives and uses thereof |
| WO2018166461A1 (en) | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001273115C1 (en) * | 2000-06-29 | 2009-03-26 | Quick Med Technologies, Inc. | Cosmetic composition and method |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| BRPI0905955A8 (pt) * | 2008-02-04 | 2018-05-08 | Lay Line Genomics Spa | anticorpo ani trka, anticorpo ou derivado, derivado de um anticorpo, combinação de um anticorpo ou derivado, composição farmaceutica, método, polipetídeo, ácido nucléico codificante de um aniticorpo ou derivado do mesmo, vetor, sistema de expressão ,mamífero transgênico não humano e kit compreendo um anticorpo ou derivado |
| US9539324B2 (en) * | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US20150183885A1 (en) * | 2012-06-08 | 2015-07-02 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
| US20170362327A1 (en) * | 2015-04-24 | 2017-12-21 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain |
| AU2020281378B2 (en) * | 2019-05-30 | 2025-09-11 | Sunshine Lake Pharma Co., Ltd. | Anti-TrkA antibodies and uses thereof |
-
2021
- 2021-11-18 AU AU2021382828A patent/AU2021382828A1/en active Pending
- 2021-11-18 WO PCT/CN2021/131343 patent/WO2022105814A1/en not_active Ceased
- 2021-11-18 CN CN202111365634.3A patent/CN114516917B/zh active Active
- 2021-11-18 US US17/911,571 patent/US20230357411A1/en active Pending
- 2021-11-18 EP EP21893961.9A patent/EP4247852A4/en active Pending
- 2021-11-18 JP JP2022555685A patent/JP7837873B2/ja active Active
- 2021-11-19 TW TW110143134A patent/TWI880048B/zh active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003501103A (ja) | 1999-06-10 | 2003-01-14 | アブジェニックス インク. | 非同種スイッチ領域を介して、ヒト抗体の特定のアイソタイプを産生するためのトランスジェニック動物 |
| JP2015520182A (ja) | 2012-06-08 | 2015-07-16 | グレンマーク ファーマシューティカルズ, エセ.アー. | アミノ酸置換を有するヒト化抗TrkA抗体 |
| US20160244529A1 (en) | 2012-06-13 | 2016-08-25 | Rottapharm Biotech S.R.L. | Anti-trka antibodies, derivatives and uses thereof |
| WO2018166461A1 (en) | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114516917A (zh) | 2022-05-20 |
| CN114516917B (zh) | 2022-11-18 |
| AU2021382828A1 (en) | 2022-10-06 |
| WO2022105814A1 (en) | 2022-05-27 |
| TWI880048B (zh) | 2025-04-11 |
| TW202227500A (zh) | 2022-07-16 |
| US20230357411A1 (en) | 2023-11-09 |
| EP4247852A1 (en) | 2023-09-27 |
| JP2023549300A (ja) | 2023-11-24 |
| EP4247852A4 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3845561A1 (en) | Anti-cd47 antibody and application thereof | |
| CN101939337B (zh) | 抗trka抗体及其衍生物 | |
| TWI908724B (zh) | TrkA的抗體及其應用 | |
| EP4148068A1 (en) | Anti-tigit antibody and preparation method and application thereof | |
| KR20200139725A (ko) | Her3 항원 결합 분자 | |
| CN111032688A (zh) | 用于延长的血清半衰期的工程化抗体fc变体 | |
| EP3247728A1 (en) | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof | |
| CN111819201A (zh) | Pd1结合剂 | |
| CN111788229A (zh) | Csf1r结合剂 | |
| TWI880048B (zh) | 人源化抗TrkA的抗體及其應用 | |
| JP7849148B2 (ja) | 抗cd26抗体の奏効性バイオマーカー | |
| WO2025241702A1 (zh) | 靶向hla-g的抗体或其抗原结合片段及其应用 | |
| WO2025241703A1 (zh) | 高亲和力b7h7抗体或其抗原结合片段及其用途 | |
| WO2025256571A1 (zh) | 靶向b7h7和cd3的双特异性抗体及其应用 | |
| KR20250124805A (ko) | Cd24에 대한 항체 및 이의 용도 | |
| KR20230142838A (ko) | 항-vegf 항체 및 이의 용도 | |
| CN115572330A (zh) | 一种特异性抗体及其制备方法和应用 | |
| WO2026026847A1 (zh) | 一种b7-h3特异性抗体及其抗肿瘤应用 | |
| KR20260062948A (ko) | Ctla4/tigit 결합 단백질 및 이의 의학적 용도 | |
| CN117715932A (zh) | 一种cdc平台抗体 | |
| OA18848A (en) | Anti - TRKA antibodies and derivatives thereof. | |
| KR20120130478A (ko) | TNF?α 특이적 항체 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260310 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260318 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7837873 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |